Skip to Main Content

CAMBRIDGE, Mass. — No one seems to quite know who gave Werewolf Therapeutics its name. But it’s very clear where the new startup, founded in 2017 by MPM Capital, got its lab space and its staff: Potenza Therapeutics.

Potenza’s lab space at 1030 Massachusetts Ave. has barely had time to get cold after Japanese drug maker Astellas (ALPMY) acquired the company in December, but the company’s former leadership team is planning to move back in as Werewolf on April 1, the company’s vice president of research and development, Cynthia Seidel-Dugan, told Cambridge regulators on Thursday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!